July 12, 2023
Guest: Matthias G. von Herrath
Listen Time: 27m
Type 1 diabetes (T1D) has long posed significant challenges for patients and researchers alike. But now, microscopic clusters of organisms are providing a glimmer of hope. Emerging as a new frontier in T1D treatment, stem cell-derived islet cell therapy is a novel approach that may revolutionize the lives of patients with this chronic disease.
“The hope is that this can make a real difference by replacing damaged cells with lab-generated human islet-like cell clusters that produce normal amounts of insulin on demand,” said Matthias von Herrath, M.D., Scientific director of the Diabetes Research Institute at the University of Miami Miller School of Medicine.
